Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients
Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular
disease risk associated with depression and anxiety. The purpose of this study is to
determine if quetiapine treatment of depression can reverse the signs of arterial stiffening
that often occurs in depression and anxiety, and which are believed to be risk factors for
future heart disease.